Alkermes is emphasizing a profitable commercial foundation, the advancement of its lead orexin 2 receptor agonist candidate ALKS 2680 into Phase 3 testing, and an expanding pipeline intended to broaden the company's footprint in neuroscience. The company completed its acquisition of Avadel, accelerating entry into the sleep medicine market with LUMRYZ, an FDA-approved product.
Cyborg Score Rationale
Alkermes demonstrates a solid commercial foundation with $1.4B+ in revenues, recent FDA Breakthrough designation for ALKS 2680, and strategic acquisition of Avadel to diversify the sleep medicine portfolio. Phase 3 initiation planned for Q1 2026 represents critical near-term catalyst. Execution risks on pipeline remain.
Top Insights
FDA granted Breakthrough Therapy designation to alixorexton for treatment of narcolepsy type 1, based on phase 1 and phase 2 clinical data
Avadel acquisition became effective on February 12, 2026, adding LUMRYZ to commercial portfolio
Alkermes plans to initiate a registrational Phase 3 narcolepsy program in Q1 2026 following an end-of-Phase 2 meeting with the FDA
Company is advancing an orexin platform with ALKS 7290 entering ADHD proof-of-concept studies in 2026 and ALKS 4510 planned for Phase 2a trials targeting fatigue in multiple sclerosis and Parkinson's disease in 2026
Named Competitors
Vyvanse — ADHD treatment; potential competitor for future ALKS 7290 ADHD program
Xyrem — Sodium oxybate for narcolepsy; established competitor in sleep medicine
Risperdal/Aripiprazole — Antipsychotics for schizophrenia; established market leader
Recent Developments
(February 2026) Completed acquisition of Avadel Pharmaceuticals, adding LUMRYZ to commercial portfolio
(January 2026) FDA grants Breakthrough Therapy designation for alixorexton in narcolepsy type 1
(January 2026) J.P. Morgan Healthcare Conference presentation outlining 2026 strategy and pipeline expansion
Open the full interactive Alkermes plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.